PT3278800T - Composições e métodos para melhorar a função mitocondrial e tratar condições patológicas relacionadas com músculos - Google Patents
Composições e métodos para melhorar a função mitocondrial e tratar condições patológicas relacionadas com músculosInfo
- Publication number
- PT3278800T PT3278800T PT17186188T PT17186188T PT3278800T PT 3278800 T PT3278800 T PT 3278800T PT 17186188 T PT17186188 T PT 17186188T PT 17186188 T PT17186188 T PT 17186188T PT 3278800 T PT3278800 T PT 3278800T
- Authority
- PT
- Portugal
- Prior art keywords
- compositions
- methods
- pathological conditions
- mitochondrial function
- treating muscle
- Prior art date
Links
- 230000004898 mitochondrial function Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 210000003205 muscle Anatomy 0.000 title 1
- 230000001575 pathological effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/31—Foods, ingredients or supplements having a functional effect on health having an effect on comfort perception and well-being
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201061426957P | 2010-12-23 | 2010-12-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3278800T true PT3278800T (pt) | 2019-08-23 |
Family
ID=45476689
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT17186188T PT3278800T (pt) | 2010-12-23 | 2011-12-23 | Composições e métodos para melhorar a função mitocondrial e tratar condições patológicas relacionadas com músculos |
Country Status (18)
Country | Link |
---|---|
US (10) | US9872850B2 (pt) |
EP (4) | EP2654461B1 (pt) |
JP (6) | JP6054301B2 (pt) |
KR (3) | KR102072612B1 (pt) |
CN (3) | CN113142581A (pt) |
AU (5) | AU2011348068B2 (pt) |
BR (1) | BR112013016230B1 (pt) |
CA (3) | CA3108114C (pt) |
CO (1) | CO6781551A2 (pt) |
ES (2) | ES2675345T3 (pt) |
HK (1) | HK1250643B (pt) |
IL (2) | IL227071A (pt) |
MX (1) | MX354875B (pt) |
PH (1) | PH12020500169A1 (pt) |
PT (1) | PT3278800T (pt) |
RU (2) | RU2606763C2 (pt) |
SG (3) | SG10201602286RA (pt) |
WO (1) | WO2012088519A2 (pt) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1929995A1 (en) | 2006-12-04 | 2008-06-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anaplerotic therapy of Huntington disease and other polyglutamine diseases |
KR102072612B1 (ko) | 2010-12-23 | 2020-02-04 | 아마젠티스 에스에이 | 미토콘드리아 기능을 개선하고 신경퇴화 질환들 및 인지 장애들을 치료하는 조성물들 및 방법들 |
US9040082B2 (en) | 2011-06-24 | 2015-05-26 | K-Pax Pharmaceuticals, Inc. | Compositions and methods for treatment of chronic fatigue |
EP2741757B1 (en) | 2011-09-11 | 2018-05-16 | Minovia Therapeutics Ltd. | Compositions of functional mitochondria and uses thereof |
WO2013132487A1 (en) * | 2012-03-07 | 2013-09-12 | Ganir (1992) Ltd. | Pomegranate extract for use in treating rhinitis and sinusitis |
KR20210128511A (ko) | 2012-06-27 | 2021-10-26 | 아마젠티스 에스에이 | 우롤리틴 또는 이의 전구체를 투여에 의한 자가포식 향상 또는 장수 증가 |
WO2014042261A1 (ja) * | 2012-09-13 | 2014-03-20 | 森下仁丹株式会社 | サーチュイン遺伝子活性増強剤ならびにそれを用いた医薬品、化粧品、および食品 |
CA2894456C (en) | 2012-12-13 | 2022-06-28 | Baylor Research Institute | Triheptanoin for the treatment of glucose transporter 1 deficiency |
AU2014206777A1 (en) * | 2013-01-18 | 2015-07-09 | Procell Sprl | Urolithin B for muscle growth |
ES2510216B1 (es) * | 2013-03-20 | 2015-10-27 | Consejo Superior De Investigaciones Científicas (Csic) | Microorganismo capaz de convertir ácido elágico y elagitaninos en urolitinas y uso del mismo |
US9325581B2 (en) * | 2013-04-02 | 2016-04-26 | International Business Machines Corporation | Context-aware management of applications at the edge of a network |
WO2015035391A1 (en) * | 2013-09-09 | 2015-03-12 | Natreon, Inc. | Regulation of body weight gain by using dibenzo-alpha-pyrones |
EP2862568A1 (en) | 2013-10-15 | 2015-04-22 | Centre National de la Recherche Scientifique (CNRS) | Compositions comprising urolithins and uses thereof for the stimulation of insulin secretion |
CA2929601A1 (en) * | 2013-11-14 | 2015-05-21 | Karin Borges | Neurodegenerative disorders and methods of treatment and diagnosis thereof |
WO2015100213A2 (en) | 2013-12-23 | 2015-07-02 | Amazentis Sa | Process-scale synthesis of urolithins |
KR101640037B1 (ko) * | 2013-12-23 | 2016-07-18 | 중앙대학교 산학협력단 | 흰말채나무 추출물, 이의 분획물 또는 이로부터 분리된 신규 화합물을 포함하는 전립선 질환 치료용 조성물 |
GB201323008D0 (en) | 2013-12-24 | 2014-02-12 | Amazentis As | Compounds and uses thereof |
EP2908137A1 (en) | 2014-02-14 | 2015-08-19 | Institut Pasteur | Methods for in vitro investigating mitochondrial replication dysfunction in a biological sample, kits and uses thereof, therapeutic methods against progeroid-like syndromes or symptomes and screening method for identifying particular protease inhibitor(s) and/or nitroso-redox stress scavenger compound(s) |
US10524488B2 (en) | 2014-12-17 | 2020-01-07 | Colgate-Palmolive Company | Composition and method for reducing or treating oral inflammation |
EP3233188A4 (en) * | 2014-12-19 | 2018-11-07 | Halo Life Science, LLC | Use of ellagic acid dihydrate in pharmaceutical formulations to regulate blood glucose levels |
WO2016099947A1 (en) * | 2014-12-19 | 2016-06-23 | Halo Life Science, Llc | Use of ellagic acid dihydrate in food products and nutraceuticals |
CN114366802A (zh) * | 2015-04-22 | 2022-04-19 | 西达-赛奈医疗中心 | 用于治疗2型糖尿病的肠内递送的苦味寡肽 |
JP6740548B2 (ja) * | 2015-05-15 | 2020-08-19 | 公立大学法人岡山県立大学 | ウロリチン類を含有する育毛剤、及び、ウロリチン類を含有する5αレダクターゼ活性阻害剤 |
JP2017014154A (ja) * | 2015-07-01 | 2017-01-19 | 公立大学法人岡山県立大学 | ウロリチン類を含有するヒアルロン酸産生促進剤 |
JP6799767B2 (ja) * | 2015-07-07 | 2020-12-16 | 公立大学法人岡山県立大学 | ウロリチン類を含有するメラニン産生抑制剤 |
GB201515391D0 (en) | 2015-08-28 | 2015-10-14 | Amazentis Sa | Compositions |
GB201515387D0 (en) * | 2015-08-28 | 2015-10-14 | Amazentis Sa | Compositions |
US11166972B2 (en) * | 2015-12-24 | 2021-11-09 | Amazentis Sa | Compositions comprising nicotinamide riboside and a urolithin |
US20210161890A1 (en) * | 2015-12-31 | 2021-06-03 | Bach Pharma, Inc. | Compositions and methods for treating brain dysfunction |
EP3412274B1 (en) | 2016-02-02 | 2023-11-08 | Daicel Corporation | Urolithins-containing aqueous solution, dried solid composition thereof and production method therefor, and urolithins stabilizing method |
JP6998108B2 (ja) * | 2016-03-07 | 2022-01-18 | 株式会社ダイセル | ウロリチン類を含有するα-グルコシダーゼ活性阻害剤、およびウロリチン類を含有する血糖値上昇抑制剤 |
JP2017210444A (ja) * | 2016-05-26 | 2017-11-30 | 株式会社ダイセル | ウロリチン類を含有するリパーゼ阻害剤 |
JP6791478B2 (ja) * | 2016-05-26 | 2020-11-25 | 株式会社ダイセル | ウロリチン類を含有するアンジオテンシン変換酵素阻害剤 |
JP6948774B2 (ja) * | 2016-09-09 | 2021-10-13 | 株式会社ダイセル | ウロリチン類を含有する前駆脂肪細胞分化抑制剤 |
EP3354645A1 (en) | 2017-01-26 | 2018-08-01 | Patheon Austria GmbH & Co KG | Process for preparing urolithins |
JP7325170B2 (ja) * | 2017-02-01 | 2023-08-14 | ロート製薬株式会社 | 美容組成物及びミトコンドリアトランスファー促進剤 |
EP3592424A1 (en) * | 2017-03-08 | 2020-01-15 | Amazentis SA | Methods for improving mitophagy in subjects |
WO2018162651A1 (en) | 2017-03-08 | 2018-09-13 | Amazentis Sa | Methods for improving mitophagy in subjects |
CA3073406A1 (en) * | 2017-09-13 | 2019-03-21 | Alexera Ab | Methods for identifying therapeutic agents which interact with stk24 |
JP2019112364A (ja) * | 2017-12-26 | 2019-07-11 | 花王株式会社 | 運動調節機能向上剤 |
WO2019147652A1 (en) * | 2018-01-23 | 2019-08-01 | The General Hospital Corporation | Compositions and methods for improving mitochondrial function |
AU2018408840A1 (en) * | 2018-02-19 | 2020-09-10 | Natreon, Inc. | Synergistic combinations of Urolithins A and B for improving cognitive capacity or cognitive function |
WO2019163176A1 (ja) * | 2018-02-21 | 2019-08-29 | 株式会社ダイセル | ウロリチン類を含有する破骨細胞分化抑制剤 |
WO2019163437A1 (ja) | 2018-02-21 | 2019-08-29 | 株式会社ダイセル | ウロリチン類を含有する破骨細胞分化抑制剤 |
JP7124367B2 (ja) * | 2018-03-20 | 2022-08-24 | トヨタ自動車株式会社 | 作業支援システム、情報処理方法およびプログラム |
JP7458368B2 (ja) | 2018-07-22 | 2024-03-29 | ミノヴィア セラピューティクス リミテッド | 筋疾患のミトコンドリア増強療法 |
RU2712193C1 (ru) * | 2018-07-27 | 2020-01-24 | Общество с ограниченной ответственностью научно-технический центр "БиоКлиникум" (ООО НТЦ "БиоКлиникум") | Способ лечения поражения нервной системы с помощью рекомбинантной глутаматоксалоацетаттрансаминазы |
MY184810A (en) * | 2018-09-03 | 2021-04-23 | Univ Kebangsaan Malaysia Ukm | A formulation that reduces oxidative stress |
CA3127590A1 (en) | 2019-01-28 | 2020-08-06 | Mitochondria Emotion, Inc. | Mitofusin activators and methods of use thereof |
AU2020215510A1 (en) | 2019-01-28 | 2021-07-22 | Mitochondria Emotion, Inc. | Trans-4-hydroxycyclohexyl phenyl amide mitofusin activators and methods of use thereof |
JP2019142863A (ja) * | 2019-02-28 | 2019-08-29 | ヒルズ・ペット・ニュートリシャン・インコーポレーテッド | 口内炎症を減少または治療するための組成物および方法 |
TWI706780B (zh) * | 2019-03-27 | 2020-10-11 | 台灣粒線體應用技術股份有限公司 | 粒線體用於製備治療阿茲海默症之醫藥組合物的用途 |
CN110517776B (zh) * | 2019-08-16 | 2023-06-16 | 四川大学华西医院 | 一种老年人健康风险评估方法及其应用 |
RU2712023C1 (ru) * | 2019-08-19 | 2020-01-24 | Федеральное государственное бюджетное учреждение науки "Институт общей и экспериментальной биологии Сибирского отделения Российской академии наук" | Способ получения уролитина d, обладающего гипогликемическим действием |
GB201912107D0 (en) | 2019-08-22 | 2019-10-09 | Amazentis Sa | Combination |
GB201915191D0 (en) | 2019-10-21 | 2019-12-04 | Floratek Gmbh | Novel heterocyclic compounds |
CN110693880A (zh) * | 2019-10-24 | 2020-01-17 | 广州中医药大学第一附属医院 | 一种尿石素制剂及其应用 |
GB201916046D0 (en) | 2019-11-04 | 2019-12-18 | Amazentis Sa | Diagnostic method |
US20230030835A1 (en) * | 2019-12-23 | 2023-02-02 | Metagenics, Inc. | Polyphenol compositions and uses thereof |
CN111658630B (zh) * | 2020-07-21 | 2021-03-23 | 温州医科大学附属第一医院 | 玫瑰酸c在制备预防和/或治疗癫痫的药物中的应用 |
JP2023542320A (ja) | 2020-09-25 | 2023-10-06 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | 水性マトリックス中で少なくとも1つのウロリチンを安定化させるためのキサンタンガムを使用する組成物及び方法 |
CN112401240A (zh) * | 2020-12-10 | 2021-02-26 | 泓博元生命科技(深圳)有限公司 | 线粒体运动营养组合物 |
KR102623664B1 (ko) * | 2020-12-10 | 2024-01-12 | 서울대학교산학협력단 | 유로리틴 a를 이용한 당뇨성 알츠하이머병의 치료 조성물 및 치료 방법 |
CN112675165A (zh) * | 2021-01-22 | 2021-04-20 | 新疆医科大学 | 鞣花酸及其代谢物作为天然抑制剂在制备抗细胞焦亡药物的应用 |
US11820751B2 (en) | 2021-01-27 | 2023-11-21 | Vandria Sa | Urolithin derivatives and methods of use thereof |
CN112957690B (zh) * | 2021-02-03 | 2021-12-14 | 台州职业技术学院 | 脑损伤大鼠多功能康复训练装置 |
CA3224861A1 (en) * | 2021-06-22 | 2022-12-29 | Tsi Usa, Llc | Compositions containing adenosine triphosphate (atp) and methods of use for cognitive function |
WO2023031673A1 (en) * | 2021-08-30 | 2023-03-09 | Amazentis Sa | Treating long covid-19 with urolithins |
WO2023079366A1 (en) * | 2021-11-08 | 2023-05-11 | Ultimate Medicine Ag | Methods and compositions for treating microglial dysfunction and improving metabolic dysfunction |
AU2022423568A1 (en) * | 2021-12-20 | 2024-05-23 | Société des Produits Nestlé S.A. | Compositions comprising urolithin for treating muscle decline and a kidney dysfunction |
WO2023161453A1 (en) | 2022-02-24 | 2023-08-31 | Amazentis Sa | Uses of urolithins |
WO2023180214A1 (en) | 2022-03-22 | 2023-09-28 | Amazentis Sa | Compositions |
CN116920001A (zh) * | 2022-03-30 | 2023-10-24 | 福建中益制药有限公司 | 一种降低高尿酸的中药组合物及其制备方法 |
WO2023228994A1 (ja) * | 2022-05-25 | 2023-11-30 | 株式会社ダイセル | Sirt3遺伝子発現増強用組成物 |
WO2024058984A2 (en) * | 2022-09-16 | 2024-03-21 | MarvelBiome, Inc. | Methods and uses of microbiome compositions, components, or metabolites for treating insulin-associated diseases |
CN115462488B (zh) * | 2022-10-08 | 2024-01-16 | 河南师范大学 | 鞣花酸作为饲料添加剂的应用,功能性饲料及制备方法 |
CN115581689B (zh) * | 2022-10-17 | 2024-05-14 | 常州大学 | 尿石素b酰胺类衍生物的应用 |
CN115969852B (zh) * | 2022-10-17 | 2024-06-18 | 常州大学 | 甲氧基尿石素a酰胺类衍生物的应用 |
EP4356757A1 (en) | 2022-10-18 | 2024-04-24 | Consejo Superior de Investigaciones Científicas (CSIC) | Microbial method for reproducing the human urolithin metabotypes in vitro and in vivo |
WO2024096818A1 (en) * | 2022-10-31 | 2024-05-10 | Delightex Pte. Ltd. | Compositions and methods for enhancing mental wellbeing |
CN115569131A (zh) * | 2022-11-03 | 2023-01-06 | 北京工商大学 | 尿石素a在抗抑郁药物及抗抑郁保健食品中的应用 |
GB202219317D0 (en) | 2022-12-20 | 2023-02-01 | Amazentis Sa | Methods for improving mitophagy in subjects |
KR102612714B1 (ko) * | 2023-01-03 | 2023-12-11 | 한림대학교 산학협력단 | 디티아논에 의해 유도된 도파민 신경 손상 관련 증상의 경감용 조성물 및 신경 손상 관련 증상의 경감 방법 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1002893A (en) | 1910-02-07 | 1911-09-12 | Joe R Wood | Rope-clip. |
JPH02304080A (ja) | 1989-05-17 | 1990-12-17 | Toyo Pharma- Kk | 6H―ジベンゾ[b,d]ピラン―6―オン誘導体,その製法及び用途 |
US5411757A (en) * | 1989-11-09 | 1995-05-02 | Buist; Neil R. M. | Palatable balanced amino acid-modified diet |
KR20000019718A (ko) * | 1998-09-15 | 2000-04-15 | 박호군 | 탄닌 또는 탄닌 유래 페놀성 화합물을 포함하는 동맥경화증, 고지혈증 및 간질환의 예방 및 치료용 조성물 |
US20030078212A1 (en) * | 1998-10-30 | 2003-04-24 | Jia-He Li | Pharmaceutical compositions containing poly(adp-ribose) glycohydrolase inhibitors and methods of using the same |
US7611738B2 (en) | 2005-05-24 | 2009-11-03 | Pom Wonderful, Llc | Processes for extracting phytochemicals from pomegranate solids and compositions and methods of use thereof |
US7727563B2 (en) * | 1999-04-19 | 2010-06-01 | Pom Wonderful, Llc | Methods of using pomegranate extracts for treating diabetes related atherosclerotic complications in humans |
US20010047032A1 (en) | 1999-12-30 | 2001-11-29 | Castillo Gerardo M. | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases |
US6670140B2 (en) * | 2001-03-06 | 2003-12-30 | The Procter & Gamble Company | Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors |
US6440436B1 (en) | 2001-05-18 | 2002-08-27 | Natreon Inc. | Process for preparing purified shilajit composition from native shilajit |
US20080039179A1 (en) | 2001-06-27 | 2008-02-14 | Seelig Jerald C | Gaming display with moveable indicator and methods of use |
US6503506B1 (en) | 2001-08-10 | 2003-01-07 | Millenium Biotechnologies, Inc. | Nutrient therapy for immuno-compromised patients |
CN100339090C (zh) * | 2002-06-04 | 2007-09-26 | 枣庄市清泽源生物科技有限公司 | 新的石榴叶提取物及其医药用途 |
WO2005000330A1 (en) | 2003-05-28 | 2005-01-06 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Angiogenic agents from plant extracts, gallic acid, and derivatives |
CN1483343A (zh) * | 2003-07-31 | 2004-03-24 | 枣庄绿宝石榴产品有限公司 | 一种石榴食用品及其制备方法和应用 |
NZ529860A (en) * | 2003-11-28 | 2006-10-27 | Ovita Ltd | Muscle growth regulator mighty and use in promoting muscle mass and treating muscle wasting diseases |
DK1734949T3 (en) | 2004-03-24 | 2015-08-24 | Univ California | Remediation of ellagitannins |
US20050282781A1 (en) | 2004-06-18 | 2005-12-22 | Shibnath Ghosal | Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids |
CN101039683A (zh) * | 2004-08-13 | 2007-09-19 | 血管技术国际有限公司 | 使用透明质酸和透明质酸酶抑制剂的组合物和方法 |
US20080214656A1 (en) * | 2004-08-23 | 2008-09-04 | Neurogenex Co., Ltd. | Compounds With Diphenoyl-Structure For the Treatment of Immune Diseases |
US8183282B2 (en) * | 2006-04-26 | 2012-05-22 | The Regents Of The University Of California | Therapeutic uses of urolithins |
EP2036551B1 (en) * | 2006-07-05 | 2013-11-06 | Kao Corporation | Catechins for improving muscle power |
US20080021340A1 (en) * | 2006-07-19 | 2008-01-24 | Mika Sarkela | Detection of focal epileptiform activity |
US20080031979A1 (en) * | 2006-08-04 | 2008-02-07 | Claude Saliou | Use of extracts for the treatment of viral disorders |
US8894993B2 (en) | 2006-08-04 | 2014-11-25 | Natreon Inc. | Mitochondria-targeted antioxidants |
US20080199546A1 (en) * | 2006-10-24 | 2008-08-21 | Krempin David W | Anti-resorptive and bone building dietary supplements and methods of use |
US8017147B2 (en) | 2008-04-07 | 2011-09-13 | Mazed Mohammad A | Nutritional supplement for the prevention of cardiovascular disease, alzheimer's disease, diabetes, and regulation and reduction of blood sugar and insulin resistance |
US8367072B2 (en) | 2006-12-08 | 2013-02-05 | Polifenoles Naturales, S.L. | Composition for treating obesity and method of using the same |
US7972633B2 (en) | 2007-02-07 | 2011-07-05 | Applied Cognitive Sciences, LLC | Nutritional supplements for healthy memory and mental function |
EP2155186A2 (fr) * | 2007-05-11 | 2010-02-24 | Galderma Research & Development | Preparations pharmaceutiques ou cosmetiques pour application topique et/ou parenterale, leurs procedes de preparation, et leurs utilisations |
CN100589813C (zh) * | 2007-05-30 | 2010-02-17 | 桂林莱茵生物科技股份有限公司 | 一种石榴皮提取物及其制备方法 |
EP2033526A1 (en) * | 2007-09-07 | 2009-03-11 | Probelte Pharma, S.A. | Nutritional products comprising pomegranate extracts containing ellagitannins and their use |
CN101254223A (zh) * | 2008-03-04 | 2008-09-03 | 东莞市竟恒流通研究所 | 石榴皮和石榴籽提取物改善***症状的新用途 |
US7927633B2 (en) | 2008-03-28 | 2011-04-19 | Janiece Diane Swilling | Adaptogenic tea |
CN101273790B (zh) * | 2008-04-22 | 2011-09-28 | 吐地·艾力 | 一种石榴原汁的制备方法 |
WO2009153652A2 (en) * | 2008-06-19 | 2009-12-23 | Avesthagen Limited | An extract and a process thereof (pomplex) |
US20100004334A1 (en) * | 2008-07-01 | 2010-01-07 | Mead Johnson Nutrition Company | Nutritional Compositions Containing Punicalagins |
CN101301319A (zh) | 2008-07-09 | 2008-11-12 | 中国科学院新疆理化技术研究所 | 石榴花多酚的制备方法及其应用 |
US20100055247A1 (en) | 2008-08-29 | 2010-03-04 | Tirrito Salvatore J | Nutritional Compositions for Athletes |
KR101046126B1 (ko) * | 2008-11-28 | 2011-07-01 | 고려대학교 산학협력단 | 석류 추출물을 포함하는 신경계 질환 예방 또는 치료용 조성물 |
KR101099718B1 (ko) * | 2008-12-26 | 2011-12-28 | 고흥석류친환경영농조합법인 | 석류 추출물을 함유하는 비만 예방 및 치료용 조성물 |
JP5385686B2 (ja) | 2009-06-05 | 2014-01-08 | サントリーホールディングス株式会社 | 血小板凝集抑制剤 |
SG10201500620PA (en) * | 2009-07-24 | 2015-03-30 | Amazentis Sa | Compounds, compositions and methods for protecting brain health in neurodegenerative disorders |
CN101695511B (zh) * | 2009-10-29 | 2012-10-17 | 新疆维吾尔自治区药物研究所 | 石榴皮提取物及其生产方法和应用 |
KR102072612B1 (ko) | 2010-12-23 | 2020-02-04 | 아마젠티스 에스에이 | 미토콘드리아 기능을 개선하고 신경퇴화 질환들 및 인지 장애들을 치료하는 조성물들 및 방법들 |
FR2975008B1 (fr) | 2011-05-13 | 2014-03-07 | Inst Biophytis | Utilisation de composes et composition pour le traitement de la degenerescence maculaire liee a l'age (dmla) |
-
2011
- 2011-12-23 KR KR1020197006027A patent/KR102072612B1/ko active IP Right Grant
- 2011-12-23 RU RU2013134197A patent/RU2606763C2/ru active
- 2011-12-23 SG SG10201602286RA patent/SG10201602286RA/en unknown
- 2011-12-23 CA CA3108114A patent/CA3108114C/en active Active
- 2011-12-23 CA CA2822898A patent/CA2822898C/en active Active
- 2011-12-23 EP EP11808119.9A patent/EP2654461B1/en active Active
- 2011-12-23 CN CN202110244520.7A patent/CN113142581A/zh active Pending
- 2011-12-23 CN CN201180067142.4A patent/CN103442594B/zh active Active
- 2011-12-23 CA CA3185480A patent/CA3185480A1/en active Pending
- 2011-12-23 JP JP2013546456A patent/JP6054301B2/ja active Active
- 2011-12-23 AU AU2011348068A patent/AU2011348068B2/en active Active
- 2011-12-23 RU RU2016147574A patent/RU2745439C2/ru active
- 2011-12-23 SG SG10202008097VA patent/SG10202008097VA/en unknown
- 2011-12-23 MX MX2013007262A patent/MX354875B/es active IP Right Grant
- 2011-12-23 ES ES11808119.9T patent/ES2675345T3/es active Active
- 2011-12-23 US US13/336,841 patent/US9872850B2/en active Active
- 2011-12-23 BR BR112013016230-9A patent/BR112013016230B1/pt active IP Right Grant
- 2011-12-23 WO PCT/US2011/067229 patent/WO2012088519A2/en active Application Filing
- 2011-12-23 KR KR1020137019369A patent/KR101955001B1/ko active IP Right Grant
- 2011-12-23 SG SG2013048160A patent/SG191297A1/en unknown
- 2011-12-23 ES ES17186188T patent/ES2734812T3/es active Active
- 2011-12-23 EP EP18166896.3A patent/EP3372228A1/en active Pending
- 2011-12-23 EP EP17186188.3A patent/EP3278800B1/en active Active
- 2011-12-23 EP EP18166897.1A patent/EP3369420A1/en active Pending
- 2011-12-23 KR KR1020187001716A patent/KR101955004B1/ko active IP Right Grant
- 2011-12-23 PT PT17186188T patent/PT3278800T/pt unknown
- 2011-12-23 CN CN201510862701.0A patent/CN105497014B/zh active Active
-
2013
- 2013-06-20 IL IL227071A patent/IL227071A/en active IP Right Grant
- 2013-07-22 CO CO13172849A patent/CO6781551A2/es not_active Application Discontinuation
-
2014
- 2014-04-24 HK HK18110108.8A patent/HK1250643B/zh unknown
-
2015
- 2015-03-11 US US14/644,912 patent/US11234960B2/en active Active
- 2015-03-12 US US14/656,096 patent/US10028932B2/en active Active
-
2016
- 2016-07-25 US US15/218,790 patent/US10485782B2/en active Active
- 2016-07-25 US US15/218,663 patent/US10857126B2/en active Active
- 2016-08-02 AU AU2016210622A patent/AU2016210622B2/en active Active
- 2016-11-30 JP JP2016232949A patent/JP6254667B2/ja active Active
-
2017
- 2017-06-15 IL IL252951A patent/IL252951A0/en active IP Right Grant
- 2017-11-30 JP JP2017230245A patent/JP6539331B2/ja active Active
-
2018
- 2018-06-08 AU AU2018204108A patent/AU2018204108B2/en active Active
- 2018-06-18 US US16/011,217 patent/US11166937B2/en active Active
-
2019
- 2019-06-07 JP JP2019107063A patent/JP6871304B2/ja active Active
-
2020
- 2020-01-23 PH PH12020500169A patent/PH12020500169A1/en unknown
- 2020-02-28 AU AU2020201476A patent/AU2020201476B2/en active Active
- 2020-07-14 US US16/928,200 patent/US11903922B2/en active Active
-
2021
- 2021-04-15 JP JP2021068968A patent/JP7174102B2/ja active Active
-
2022
- 2022-01-14 US US17/576,502 patent/US12036205B2/en active Active
- 2022-01-27 AU AU2022200531A patent/AU2022200531B2/en active Active
- 2022-11-04 JP JP2022177180A patent/JP2022190124A/ja active Pending
-
2023
- 2023-07-17 US US18/353,570 patent/US20240100016A1/en active Pending
-
2024
- 2024-01-19 US US18/417,731 patent/US20240156777A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1250643B (zh) | 用於改善線粒體功能以及治療肌肉相關病理狀況的組合物和方法 | |
HK1214521A1 (zh) | 用於治療蛋白質病的組合物和方法 | |
HK1209798A1 (en) | Compositions and methods for treating cancer | |
HK1203566A1 (en) | Methods and compositions for treating huntingtons disease | |
IL269166A (en) | Methods and preparations for treating inflammation | |
EP2836482A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER | |
EP2890720A4 (en) | COMPOSITIONS AND METHODS OF TREATING CANCER | |
EP2655334A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES | |
EP2755482A4 (en) | COMPOSITIONS AND METHODS OF TREATING CANCER | |
EP2665521A4 (en) | COMPOSITIONS AND METHODS FOR TREATING CANCER | |
EP2544655A4 (en) | COMPOSITIONS AND METHODS FOR TREATING SKIN | |
SG10201500124VA (en) | Methods and Compositions for Treating Cancer | |
EP2590674A4 (en) | COMPOSITIONS AND METHODS FOR INFLUENZA TREATMENT | |
EP2523553A4 (en) | METHOD AND COMPOSITIONS FOR TREATING BLOOD DISORDER | |
EP2922919A4 (en) | COMPOSITIONS AND METHODS FOR REDUCING OXIDATIVE DAMAGES | |
HK1216854A1 (zh) | 用於治療癌症的組合物和方法 | |
EP2863939A4 (en) | COMPOSITIONS AND METHODS FOR TREATING VITILIGO | |
EP2726109A4 (en) | COMPOSITIONS AND METHODS FOR TREATING SKELETAL MYOPATHY | |
EP2707020A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | |
EP2931280A4 (en) | METHOD AND COMPOSITIONS FOR INHIBITING CNKSR1 | |
IL225483A0 (en) | The compositions and methods for the treatment of neoplasia | |
HK1211852A1 (en) | Methods and compositions for treating progesterone-dependent conditions | |
ZA201305497B (en) | Methods and compositions for preventing and treating osteoarthritis | |
HK1214267A1 (zh) | 組合物和改善葡萄糖攝取的方法 | |
EP2582384A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER |